Cytomx Therapeutics Stock Performance
| CTMX Stock | USD 0.89 0.02 2.30% |
The firm shows a Beta (market volatility) of 1.12, which signifies a somewhat significant risk relative to the market. CytomX Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, CytomX Therapeutics is expected to follow. At this point, CytomX Therapeutics has a negative expected return of -0.39%. Please make sure to confirm CytomX Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if CytomX Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CytomX Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's primary indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Disposition of 37500 shares by Mccarthy Sean A. of CytomX Therapeutics subject to Rule 16b-3 | 09/03/2024 |
2 | CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients with Solid Tumors | 09/09/2024 |
3 | Acquisition by Marcia Belvin of 60000 shares of CytomX Therapeutics subject to Rule 16b-3 | 09/23/2024 |
4 | Disposition of 16535 shares by Mccarthy Sean A. of CytomX Therapeutics at 1.5749 subject to Rule 16b-3 | 10/14/2024 |
5 | Alphina Therapeutics Appoints Veteran Biotech Executive, Nick Galli, as Chief Executive Officer | 10/23/2024 |
6 | Earnings To Watch CytomX Therapeutics Inc Reports Q3 2024 Result | 11/06/2024 |
7 | CytomX Therapeutics Q3 Earnings and Revenues Top Estimates | 11/07/2024 |
8 | CytomX Therapeutics Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth Amid ... | 11/08/2024 |
9 | CytomX Therapeutics SWOT analysis biotech stocks potential in cancer treatment | 11/12/2024 |
10 | Biotechnology Value Fund L P Increases Stake in CytomX Therapeutics Inc | 11/15/2024 |
11 | CHMP Endorses AstraZenecas Tagrisso for Expanded Use in NSCLC | 11/19/2024 |
12 | JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer | 11/21/2024 |
| Begin Period Cash Flow | 194.6 M |
CytomX |
CytomX Therapeutics Relative Risk vs. Return Landscape
If you would invest 119.00 in CytomX Therapeutics on August 27, 2024 and sell it today you would lose (30.00) from holding CytomX Therapeutics or give up 25.21% of portfolio value over 90 days. CytomX Therapeutics is currently does not generate positive expected returns and assumes 3.4878% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than CytomX, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CytomX Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CytomX Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CytomX Therapeutics, and traders can use it to determine the average amount a CytomX Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1128
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CTMX |
Estimated Market Risk
| 3.49 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.39 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average CytomX Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CytomX Therapeutics by adding CytomX Therapeutics to a well-diversified portfolio.
CytomX Therapeutics Fundamentals Growth
CytomX Stock prices reflect investors' perceptions of the future prospects and financial health of CytomX Therapeutics, and CytomX Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CytomX Stock performance.
| Return On Equity | -54.75 | ||||
| Return On Asset | 0.0233 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | (37.34 M) | ||||
| Shares Outstanding | 78.26 M | ||||
| Price To Earning | (11.41) X | ||||
| Price To Book | 5.04 X | ||||
| Price To Sales | 0.55 X | ||||
| Revenue | 101.21 M | ||||
| Gross Profit | 53.16 M | ||||
| EBITDA | (4.31 M) | ||||
| Net Income | (569 K) | ||||
| Cash And Equivalents | 194.29 M | ||||
| Cash Per Share | 2.94 X | ||||
| Total Debt | 13.97 M | ||||
| Debt To Equity | 0.67 % | ||||
| Current Ratio | 2.05 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (56.03 M) | ||||
| Earnings Per Share | 0.16 X | ||||
| Market Capitalization | 69.65 M | ||||
| Total Asset | 201.79 M | ||||
| Retained Earnings | (723.45 M) | ||||
| Working Capital | 27.02 M | ||||
| Current Asset | 189.75 M | ||||
| Current Liabilities | 15.74 M | ||||
About CytomX Therapeutics Performance
Evaluating CytomX Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if CytomX Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CytomX Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.14) | (0.15) | |
| Return On Equity | 0.01 | 0.01 |
Things to note about CytomX Therapeutics performance evaluation
Checking the ongoing alerts about CytomX Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CytomX Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CytomX Therapeutics generated a negative expected return over the last 90 days | |
| CytomX Therapeutics has some characteristics of a very speculative penny stock | |
| CytomX Therapeutics has high historical volatility and very poor performance | |
| CytomX Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 101.21 M. Net Loss for the year was (569 K) with profit before overhead, payroll, taxes, and interest of 53.16 M. | |
| CytomX Therapeutics currently holds about 194.29 M in cash with (56.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| CytomX Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 65.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer |
- Analyzing CytomX Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CytomX Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining CytomX Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CytomX Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CytomX Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CytomX Therapeutics' stock. These opinions can provide insight into CytomX Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.